34 results
8-K
EX-99.2
dy8hnaudpqcys
13 Feb 24
Results of Operations and Financial Condition
4:10pm
424B3
pwvo6krq6qidcnv3
28 Aug 23
Prospectus supplement
9:10am
S-4/A
d7ivw64 uh36zr08vh
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
na8ke2
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-2.1
71w4vu4nrl3bdxk379
29 Jun 23
Business combination disclosure
9:10am
8-K
EX-2.1
mr4q zntla853gs
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
PRE 14A
teeg h7j1
7 Apr 23
Preliminary proxy
6:29am
8-K
EX-99.1
w8ymiub 32gii
15 Nov 22
Other Events
4:17pm
8-K
EX-99.1
9az ca485
9 Jun 22
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
8:32am
8-K
EX-99.2
7bd p3tuz
9 Jun 22
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
8:32am
8-K
EX-99.1
p1mo6t
11 Mar 22
FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
2:33pm